Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
linvoseltamab + cemiplimab
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Linvoseltamab + cemiplimab is an investigational combination therapy of two monoclonal antibodies—linvoseltamab, a bispecific antibody targeting both B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells, and cemiplimab, a fully human antibody that inhibits programmed death-1 (PD-1) on T cells. **Linvoseltamab** acts as a T-cell engager, mediating targeted lysis of BCMA-expressing plasma cells through immune synapse formation, while **cemiplimab** blocks PD-1 signaling to potentiate T cell-mediated antitumor responses. This combination is being studied for the treatment of multiple myeloma, with the aim of enhancing antitumor immune activity by both redirecting T cells to myeloma cells and relieving immune checkpoint inhibition[1][2][5][7]. Both drugs are developed by Regeneron.
- Other names
- linvoseltamab + cemiplimab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD3 (T-cell surface glycoprotein CD3)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on linvoseltamab + cemiplimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on linvoseltamab + cemiplimab.